Acne Treatment Market: By Device Type (Photodynamic, Laser, Radiofrequency, Others), By End-User Industry (Hospitals, Clinics, Salon & Spa, Individual Homes, Others), and by Geography  

Acne Treatment Market size was valued at USD 5900 million in 2022 and is expanded to grow at a significant CAGR of 4.9% from, 2023-2029. The rising psychological problems of acne among youth or across age groups are critical factors for this market's growth. Consumers are looking for safe and cost-effective options for acne treatment. Growing demand for quick and safe treatments and solid results are some of the factors projected to drive the market in the forecasted period. Acne's constant prevalence worldwide is expected to boost the growth of the acne treatment market. Acne-clearing devices aid in the healing process when used in conjunction with drugs, allowing the body to effectively treat acne, which is anticipated to drive the growth of the acne treatment market. The growing inclination of consumers toward acne treatment devices that are convenient to use at home creates an opportunity for marketers. Individuals aged 12 to 30 years old have the highest prevalence of acne, and the growing number of people in this age group is driving the market for acne treatment devices. In the acne treatment market, the salon & spa, and clinic segments are expected to contribute the highest revenue share of 36.7% in 2020. The growing number of salons with innovative treatments, increasing sedentary lifestyles, and raising awareness about upcoming trends in acne treatments may boost the market.

Acne Treatment Market Key Developments:

• In March 2022, CUTERA, INC., a leading provider of dermatology solutions, announced the U.S. Food and Drug Administrations 510(k) clearance of AviClear, the first and only energy-based device to receive this designation for the treatment of mild, moderate, and severe acne.
• In November 2021, Sun Pharmaceutical Industries Limited announced the availability of WINLEVI (clascoterone) cream 1% in the United States (U.S). A first-in-class topical androgen receptor inhibitor, WINLEVI, was approved by the U.S. Food and Drug Administration (FDA) in August 2020 for the topical treatment of acne vulgaris in patients 12 years of age and older.